Corvus Pharmaceuticals Q3 net loss more than doubles to $20.34 million
CRVS•Corvus Pharmaceuticals’ third-quarter 2026 net loss more than doubled year over year to $20.34 million. It reported $202.9 million in cash, cash equivalents and marketable securities, expected to fund operations into the second quarter of 2028.
1. Quarterly results and pipeline
Research and development expenses more than doubled to $17.78 million, primarily due to higher soquelitinib clinical trial and personnel costs. Enrollment remained on track in the drug’s registrational Phase 3 peripheral T-cell lymphoma trial and Phase 2 atopic dermatitis trial. Corvus expects initial hidradenitis suppurativa trial data in the first half of 2027 and plans to begin a Phase 2 asthma trial by Q1 2027.
